Key result
Factor XI and XII inhibitors are emerging as promising new anticoagulants in phase 2 and 3 trials, potentially offering effective thromboprophylaxis with a lower risk of major bleeding.
Why the study?
Residual cardio- and cerebrovascular risk and major bleeding remain unmet medical needs with direct anticoagulants, prompting the review of factor XI and XII inhibitors.
Design
Review
Authors
Loading...
May reduce bleeding in thromboprophylaxis if confirmed; leaves open need for phase 3 safety and efficacy data.
Inhibition of the contact coagulation pathway via Factor XI and XII represents a promising new approach to anticoagulation that may address unmet needs in high-bleeding-risk patients.
Prisco et al. (2023) conducted a review in Thrombosis and bleeding disorders. Factor XI and XII inhibitors was evaluated. Factor XI and XII inhibitors are emerging as promising new anticoagulants in phase 2 and 3 trials, potentially offering effective thromboprophylaxis with a lower risk of major bleeding.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: